---
title: "BrightGene: Subsidiary BrightGene Pharmaceutical's product Dydrogesterone Tablets is expected to win the bid for national centralized drug procurement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263063973.md"
description: "BrightGene announced that its wholly-owned subsidiary, BrightGene Pharmaceutical Co., Ltd., participated in the bidding for the 11th batch of national centralized drug procurement organized by the National Organization for Drug Procurement Office. BrightGene Pharmaceutical's product, Dydrogesterone Tablets, is expected to win the bid for this centralized procurement. Dydrogesterone Tablets received the drug registration certificate issued by the National Medical Products Administration in December 2024 and is a new product launched by the company, generating sales revenue of 1.7351 million yuan from January to September 2025"
datetime: "2025-10-28T10:56:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263063973.md)
  - [en](https://longbridge.com/en/news/263063973.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263063973.md)
generator: "portal-rs"
---

# BrightGene: Subsidiary BrightGene Pharmaceutical's product Dydrogesterone Tablets is expected to win the bid for national centralized drug procurement

BrightGene announced that its wholly-owned subsidiary, BrightGene Pharmaceutical Co., Ltd., participated in the bidding work organized by the National Organization for Drug Procurement Office for the 11th batch of national centralized drug procurement. BrightGene's product, Dydrogesterone Tablets, is expected to win the bid for this centralized procurement. Dydrogesterone Tablets received the drug registration certificate issued by the National Medical Products Administration in December 2024, making it a newly launched product for the company, generating sales revenue of 1.7351 million yuan from January to September 2025

### Related Stocks

- [688166.CN](https://longbridge.com/en/quote/688166.CN.md)

## Related News & Research

- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [Butler National Wins Three-Year Extension to Manage Kansas Sports Wagering, Retains 90% Revenue Share](https://longbridge.com/en/news/296516585.md)
- [Hengrui Pharma launches RMB 1 billion-RMB 2 billion A-share buyback, caps price at RMB 81.78](https://longbridge.com/en/news/296368941.md)
- [Rein Therapeutics releases corporate presentation on LTI-03 idiopathic pulmonary fibrosis program](https://longbridge.com/en/news/296389731.md)
- [New Buy Rating for Semiconductor Manufacturing International (0981), the Technology Giant](https://longbridge.com/en/news/296193427.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**